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Abstract
OBJECTIVE—Our goal was to evaluate the effects of simvastatin on endometrial cancer cell
lines and primary cultures of endometrial cancer cells.
METHODS—Cell proliferation in the ECC-1 and Ishikawa endometrial cancer cell lines and
primary cultures of endometrial cancer cells was assessed by MTT assay. Apoptosis and cell cycle
were detected by Annexin V assay and propidium iodide staining, respectively. Reactive oxygen
species and cell adhesion were assessed using ELISA assays. Invasion was analyzed using a
transwell invasion assay. Mitochondrial DNA damage was confirmed using qPCR. The effects of
simvastatin on the AKT/mTOR and MAPK pathways were determined by Western blotting.
RESULTS—Simvastatin inhibited cell proliferation in a dose-dependent manner in both
endometrial cancer cell lines and 5/8 primary cultures of endometrial cancer cells. Simvastatin
treatment resulted in G1 cell cycle arrest, a reduction in the enzymatic activity of HMG-CoA,
induction of apoptosis as well as DNA damage and cellular stress. Treatment with simvastatin
resulted in inhibition of the MAPK pathway and exhibited differential effects on the AKT/mTOR
pathway in the ECC-1 and Ishikawa cells. Minimal change in AKT phosphorylation was seen in
both cell lines. An increase in phosphorylated S6 was seen in ECC-1 and a decrease was seen in
Ishikawa. Treatment with simvastatin reduced cell adhesion and invasion (p<0.01) in both cell
lines.
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CONCLUSION—Simvastatin had significant anti-proliferative and anti-metastatic effects in
endometrial cancer cells, possibly through modulation of the MAPK and AKT/mTOR pathways,
suggesting that statins may be a promising treatment strategy for endometrial cancer.
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INTRODUCTION
Endometrial cancer is the fourth most common cancer among women with an estimated
49,560 new cases diagnosed in the United States in 2013 (1). The incidence of this disease
has increased over the past few decades, largely as a result of the growing obesity epidemic
(1). Obesity, diabetes and insulin resistance are well known risk factors for endometrial
cancer and may be associated with worse outcomes for this disease (2). Women with early
stage disease and low-grade endometrioid histology have a relatively good prognosis with
surgery alone or surgery plus radiation. However, those patients with advanced stage III or
IV endometrial cancer are unlikely to be cured by surgery, chemotherapy, radiation or a
combination of these treatment modalities. Given the rising incidence of this disease and the
paucity of effective treatments for advanced endometrial cancer, it is imperative to search
for novel agents for the effective management of this obesity-driven cancer.
Simvastatin, one of the 3-hydoxy-3methylglutaryl coenzyme A reductase (HMGCR)
competitive inhibitors, is a well-tolerated cholesterol reducing agent used to treat
hypercholesterolemia. HMGCR catalyzes the rate-limiting step in mevalonate synthesis,
which is essential for cellular synthesis of cholesterol and a variety of nonsteriod isoprenoid
derivatives involved in cell proliferation, differentiation and survival (3, 4). In addition to its
cholesterol-reducing effects, in vitro and in vivo studies suggest that simvastatin inhibits
cancer cell growth by inducing apoptosis and inhibiting cell cycle progression through
multiple cell signaling pathways (4–8). An association between long-term statin use and a
relative reduction in the risk of cancer has been illustrated in several studies (9–11). A recent
epidemiological study found that the use of statins was protective against the development
of endometrial cancer and was associated with improvements in endometrial cancer survival
(12). Phase II clinical trials have shown some cancer patients may benefit from simvastatin
combined with other chemotherapeutic agents (13, 14).
Little is known of whether statins impact endometrial cancer cell growth. Given that
endometrial cancer incidence and obesity are on the rise and simvastatin has demonstrated
anti-proliferative effects in other types of cancers, the aim of this study was to investigate
the effect of simvastatin on cell proliferation, apoptosis, and adhesion/invasion in
endometrial cancer cell lines and primary cultures of endometrial cancer cells.
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Cell culture and reagents
The ECC-1 and Ishikawa cell lines were provided as a gift from Dr Bruce Lessey
(Department of OB/GYN Greenville Memorial Hospital) (15). Both cell lines are estrogen
receptor-alpha positive and progesterone receptor weakly positive, which was recently
confirmed in our laboratory by chloramphenicol acetyltransferase (CAT) activity. The
ECC-1 cells were maintained in RPMI 1640 containing 5% fetal bovine serum, 300 mM l-
glutamine, 5 μg/ml bovine insulin, 10,000 U/ml penicillin and 10,000 μg/ml streptomycin
under 5% CO2. The Ishikawa cells were grown in MEM supplemented with 5% fetal bovine
serum, 300 mM l-glutamine, 10,000 U/ml penicillin and 10,000 μg/ml streptomycin under
5% CO2. Simvastatin, MTT (3-5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide)
and RNase A were purchased from Sigma (St. Louis, MO). The anti-phosphorylated-AKT,
anti-pan-AKT, anti-phosphorylated-p42/44, anti-pan-p42/44, anti-phosphorylated-S6, anti-
pan-S6, anti-cleaved caspase 3, anti-BCL-2, and anti-MCL-1 antibodies were purchased
from Cell Signaling (Beverly, MA). The anti-HMGCoA antibody was from Santa Cruz
(Dallas, Texas). Enhanced chemiluminescence Western blotting detection reagents were
purchased from Amersham (Arlington Heights, IL). All other chemicals were purchased
from Sigma.
Cell proliferation assays
The ECC-1 and Ishikawa cells were plated and grown in 96-well plates at a concentration of
4000 cells/well for 24 h. Cells were subsequently treated with varying doses of simvastatin
for 72 h. MTT (5 mg/ml) was added to the 96-well plates at 10 μl/well, followed by an
additional hour of incubation. The MTT reaction was terminated through the addition of 100
μl of DMSO. The results were read by measuring absorption at 570 nm with a Microplate
Reader (Tecan, Morrisville, NC). The effect of simvastatin was calculated as a percentage of
control cell growth obtained from DMSO treated cells grown in the same 96-well plates.
Each experiment was performed in triplicate to assess for consistency of results.
Apoptosis assay
Apoptosis was detected with the Annexin V FITC kit (Biolegend, San Diego, CA) on the
Cellometer (Nexelom, Lawrence, MA). Briefly, 2×105 cells/well were seeded into 6-well
plates, incubated overnight and then treated with simvastatin at different doses for 24 h. The
cells were then collected, washed with PBS and resuspended in 100 ul binding buffer.
Subsequently, 1 ul of annexin V-FITC (100 ug/ml) and 0.5 uL of propidium iodide (2
mg/ml) were added in the binding buffer and placed in the dark for 15 minutes. The samples
were immediately measured by Cellometer. The results were analyzed by FCS4 express
software (Molecular Devices, Sunnyvale, CA). All experiments were performed in triplicate
to assess for consistency of response.
Cell cycle assay
The effects of simvastatin on cell cycle progression were measured by Cellometer. Briefly,
2.5×105 cells/well were seeded into 6-well plates, incubated overnight and then treated with
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simvastatin at different concentrations for 24 h. The cells were harvested and washed with
phosphate buffered saline (PBS). The pellet was resuspended and fixed in 90% pre-chilled
methanol and stocked overnight at −20°C. The cells were then washed with PBS again and
resuspended in 50 μl RNase solution (Thermo Fisher 250 ug/mL) and 10 mM EDTA for 30
minutes. Finally, 50 μl staining solution [containing 2 mg/ml PI (Biotium, Hayward, MA),
0.1 mg/ml Azide (Sigma-Aldrich), and 0.05% Triton X-100 (Sigma-Aldrich)] was added,
and the final mixture was incubated for 15 minutes in the dark before being analyzed on
Cellometer. The measured results were analyzed using the FCS4 express software. Cell
cycle analysis assay was performed in duplicate.
Adhesion assay
Each well in a 96-well plate was coated with 100 ul laminin-1 (10 ug/ml) and incubated at
37°C or 1 h. The fluid was then aspirated, and 200 ul blocking buffer was added to each well
for 45–60 min at 37°C. The wells were washed with PBS, and the plate was allowed to chill
on ice. To each well, 2.5 × 103 cells were added with PBS and varying concentrations of
simvastatin directly. The plate was then allowed to incubate at 37°C for 2 h. The medium
was then aspirated, and the cells were fixed by directly adding 100 ul of 5% glutaraldehyde
and incubating for 30 min at room temperature. Adhered cells were then washed with PBS
and stained with 100 ul of 0.1% crystal violet for 30 min. The cells were washed repeatedly
with water, and 100 ul of 10% acetic acid was added to each well to solubilize the dye. After
5 minutes of shaking, the absorbance was measured at 570 nm using a microplate reader
from Tecan (Mannedorf, Switzerland). All experiments were performed in duplicate to
assess for consistency of response.
Invasion assay
Cell invasion assays were performed using 96-well HTS transwells (Corning Life Sciences,
Wilmington, NC) coated with 0.5-1X BME (Trevigen, Gaithersburg, Maryland). Starved
(serum-free media for 12 h) ECC-1 and Ishikawa cells (50,000 cells/well) were seeded for
12 h in the upper chambers of the wells in 50 μl FBS-free medium, and the lower chambers
were filled with 150 μl regular medium with different concentrations of simvastatin. The
plate was incubated for 24 h at 37°C to allow invasion into the lower chamber. After
washing the upper and lower chambers with PBS once, 100 ul Calcein AM solution was
added into the lower chamber and incubated at 37°C for 30–60 min. The lower chamber
plate was measured by the plate reader for reading fluorescence at EX/EM 485/520 nM. All
experiments were performed in duplicate to assess for consistency of response.
Reactive oxygen species (ROS) assay
ROS generation was assessed using the ROS-sensitive fluorescence indicator, DCFH-DA.
To determine intracellular ROS scavenging activity, Ishikawa and ECC-1 cells (1.0 × 104
cells/well) were seeded in black 96-well plates. After 24 h, the cells were treated with
simvastatin for 8 h to induce ROS generation. After the cells were incubated with DCFH-
DA (20 μM) for 30 minutes, the fluorescence intensity was measured at an excitation
wavelength of 485 nm and an emission wavelength of 530 nm using a fluorescence
microplate reader. All experiments were performed in duplicate to assess for consistency of
response.
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Mitochondrial DNA damage assay
Mitochondrial DNA damage was detected using a qPCR assay previously described by
Furda et. al. (16). This assay is based on the principle that many types of DNA lesions can
slow or block the progression of DNA polymerase (16). Thus, if equal quantities of DNA
from different samples are qPCR amplified under the same conditions, DNA with less
damage will amplify to a greater extent than DNA with more damage (16). This assay is
particularly sensitive in identifying ROS-mediated mitochondrial DNA damage (16). High-
molecular-weight DNA was isolated using a QIAamp DNA mini kit (QIAGEN, Venlo,
Limberg) following the recommended protocol. The concentration of total cellular DNA
was determined by using the Tecan Nanodrop. Quantitative PCR (qPCR) assays were
performed as previously described with minor modifications (16). The primers for large
fragments of the mitochondrial (mt) DNA (8.9 kb) are forward 5′ - TCA AAG CCT CCT
TAT TCG AGC CGA -3′, reverse 5′ – TTT CATCAT GCG GAG ATG TTG GAT GG - 3′,
and primers for small mtDNA (221 bp) fragment are forward 5′ – CCC CAC AAA CCC
CAT TAC TAA ACC CA -3′, reverse 5′ – TTT CATCAT GCG GAG ATG TTG GAT GG -
3′. A total volume of 50 μl was used in PCRs containing: 15 ng of template DNA, 5 pmol of
each primer, 10X mix buffer and 2.5 units of recombinant Taq DNA polymerase High
Fidelity (Invitrogen, Carlsbad, CA). A quantitative control using half the concentration of
control template DNA was included in each set of PCR reactions. Small fragments (211 bp)
of the mtDNA were also amplified for internal controls, respectively. The internal controls
were used to normalize the results obtained from the large fragments and to monitor the
mitochondrial copy number. The thermal cycling conditions were as follows: 95°C for 3
min, followed by 19 cycles of 94°C for 1 min, 64°C for 1 min and 68°C for 9 min, primer
extension at 72°C for 3 min at the end of these cycles. Every sample was tested in triplicate.
qPCR products were quantitated using the Quant-iT dsDNA High Sensitivity Assay Kit
(Life Technologies, Grand Island, NY). The average lesion frequency per each fragment was
calculated by using the Poisson equation. This experiment was done in duplicate to assess
for consistency of response.
Western immunoblotting
The Ishikawa and ECC-1 cells were plated at 2 × 105 cells/well in 6-well plates in their
corresponding media and then treated with simvastatin for 20 h. Cell lysates were prepared
in RIPA buffer (1% NP40, 0.5 sodium deoxycholate and 0.1% SDS). Equal amounts of
protein were separated by gel electrophoresis and transferred onto a PVDF membrane. The
membrane was blocked with 5% nonfat dry milk and then incubated with a 1:1000 dilution
of primary antibody overnight at 4°C. The membrane was then washed and incubated with a
secondary peroxidase-conjugated antibody for 1 h after washing. Antibody binding was
detected using an enhanced chemiluminescence detection system on the Alpha Innotech
Imaging System (Protein Simple, Santa Clara, CA). After developing, the membrane was
stripped and re-probed using antibodies against β-actin or α-tubulin to confirm equal
loading. Intensity for each band was measured and normalized to β-actin or α-tubulin as an
internal control. Each experiment was repeated two times to assess for consistency of
results.
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Endometrial cancer tissue sample collection and primary cell culture
Eight tumor specimens were sampled from patients undergoing surgery for endometrial
carcinoma at the University of North Carolina at Chapel Hill (UNC-CH). The protocol was
reviewed and exemption granted by the Institutional Review Board at UNC-CH. For the
culture of primary endometrial cancer cells, the freshly obtained tissues were washed three
times with Hank’s Buffered Salt Solution (HBSS), and then minced by scissors in
DMEM/F12 medium containing 10% fetal bovine serum (FBS). These tissues were then
digested in 0.2% collagenase IA, 100 U/ml penicillin and anti-anti for 30–60 min at 37°C
water bath with shaking. After two centrifugations with PBS solution, the cells were re-
suspended and diluted to 1×105 cells/ml with DMEM/F12 medium. 2×104 cells/well were
seeded into 96-well plates and incubated for 24 h before treatment with simvastatin. Cells
were then treated with varying doses of simvastatin. Cell proliferation was measured by
MTT assay 72 h after treatment.
HMGCR Assay
HMGCR activity was measured using the HMG-CoA reductase (HMGR) assay kit from
Sigma-Aldrich (Saint Louis, MO), following the manufacturer’s instructions. Both cell lines
were treated with simvastatin for 24 h, and proteins were collected using mammalian protein
extraction buffer. The spectrometer was operated with the Tecon I control software in time
driver mode. The absorbance at 340 nm was monitored at a time interval of 1.00 s for a total
of 15 min. This experiment was performed in duplicate.
Statistical Analysis
Results for experiments were normalized to the mean of the control and analyzed using the
Student t-test. Differences were considered significant if the p value was less than 0.05 (p <
0.05) with a confidence interval of 95%.
RESULTS
Simvastatin inhibits cell growth and decreases HMGCR activity
The effect of simvastatin on cell proliferation was examined in the endometrial cancer cell
lines, ECC-1 and Ishikawa. Both cells were exposed to varying doses of simvastatin for 72
h. As shown in Figure 1A, simvastatin effectively inhibited growth in a dose-dependent
manner in both endometrial cancer cells. The mean IC50 value for each of these cell lines
was approximately 15 uM and 17 uM for ECC-1 and Ishikawa cells, respectively. In order to
insure that simvastatin had an inhibitory effect on its molecular target, we examined
HMGCR activity in both cell lines after exposure to varying doses of simvastatin (1 and
10uM) for 24 h. A significant decrease in HMGCR activity was seen in the ECC-1 (Figure
1B) and Ishikawa cell lines (Figure 1C), co-incident with inhibition of proliferation.
Simvastatin induces cell cycle arrest in G0/G1 and apoptosis
To evaluate the underlying mechanism of growth inhibition by simvastatin, the cell cycle
profile was analyzed after treating the ECC-1 and Ishikawa cells with varying doses (1–25
uM) of simvastatin for 24 h. As illustrated in Figure 1D, simvastatin treatment resulted in
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G0/G1 cell cycle arrest and reduced S phase in a dose-dependent manner in ECC-1. Minimal
effects on G0/G1 arrest were seen in the Ishikawa cells (Figure 1E). To further confirm
whether the growth inhibition of endometrial cancer cells was related to apoptosis, we
evaluated the apoptotic effect of simvastatin on ECC-1 and Ishikawa cells by Annexin-V
FITC stain analysis, which detects the phospholipid phosphatidylserine (PS) translocation
from the inner (cytoplasmic) leaflet of the cell membrane to the external surface in very
early apoptotic cells. As shown in Figure 2A–2D, after treatment of the cells with
simvastatin at the indicated concentrations for 24 h, the percentage of early apoptotic cells
increased in a dose-dependent manner in both cell lines.
To further analyze the effects of simvastatin on apoptosis pathways, Western blot analysis
was used to detect a change in caspase-3 and other anti-apoptotic proteins. Caspase-3 is a
member of the caspase family, which are cysteine proteases that act in a cascade manner to
trigger apoptosis and are considered to be effector caspases involved in cell disassembly.
BCL-2 and MCL-1 are anti-apoptotic proteins that belong to the BCL-2 family of cell death
regulator proteins. Western blotting indicated that simvastatin increased cleaved caspase-3
and decreased BCL-2 protein expression in both cell lines while MCL-1 levels remained
constant (Figure 2E and 2F). These results suggest that simvastatin reduces cell proliferation
through inducing cell cycle G1 arrest and induction of apoptosis in endometrial cancer cells.
Furthermore, simvastatin may be involved in different cell death mechanisms to inhibit cell
proliferation in different endometrial cancer cells.
Simvastatin increased levels of intracellular ROS and resulted in DNA damage
To investigate the involvement of oxidative stress in the anti-proliferative effect of
simvastatin, intracellular ROS levels were examined by using the ROS fluorescence
indicator DCFH-DA. As seen in Figure 3A and 3B, treatment with simvastatin (1–25 uM)
for 24 h significantly increased ROS production in a dose-dependent manner in both the
ECC-1 and Ishikawa cells. Given that the production of peroxides and free radicals induced
in oxidative stress can damage several cell components including nuclear and mitochondrial
DNA, we evaluated DNA damage by qPCR and found that simvastatin induced DNA
damage in a dose-dependent manner in the ECC-1 (Figure 3C) and Ishikawa (Figure 3D)
cell lines after 24 h of treatment. These results indicate that an increase in ROS and DNA
damage might also be involved in the anti-tumorigenic effects of simvastatin in endometrial
cancer cells.
Effect of simvastatin on the AKT/mTOR and MAPK pathways
To investigate the mechanisms underlying the inhibition of cell growth by simvastatin, we
characterized the effect of simvastatin on the extracellular signal regulated kinase (ERK)/
mitogen-activated protein kinase (MAPK) and AKT/mammalian target of rapamycin (AKT/
mTOR) pathways. Simvastatin reduced phosphorylation of p42/44 (ERK1/2) in a dose-
dependent manner in both endometrial cancer cells lines, within 18 h of exposure (Figure 4A
and 4B). We then evaluated the effect of simvastatin on downstream targets of the AKT/
mTOR pathway, including phosphorylated AKT and phosphorylated ribosomal protein S6.
Simvastatin was found to decrease phosphorylation of S6 in the Ishikawa cells, whereas
simvastatin increased phosphorylation of S6 in the ECC-1 cells. There was little effect on
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phosphorylated AKT expression in either cell line after 18 h of treatment. This data suggests
that simvastatin may exert its anti-tumor activity via cell signaling pathways other than those
downstream of the mTOR pathway.
Simvastatin inhibits cell adhesion and invasion
In order to determine the effect of simvastatin on adhesion and invasion of endometrial
cancer cells, an in vitro laminin adhesion assay and a transwell invasion system were
employed. Incubation of ECC-1 and Ishikawa cells with simvastatin (1, 10 and 25 uM) for 2
h showed significant inhibition of cell adhesion (Figure 5A and 5B). Simvastatin
significantly blocked endometrial cancer cell invasion after 24 h of treatment as determined
by transwell invasion assay (Figure 5C and 5D). Inhibition of cell adhesion and invasion
was dose-dependent in both cells. These results suggest that simvastatin may function to
inhibit adhesion and invasion in endometrial cancer cells as well as inducing apoptosis, cell
cycle arrest and cellular stress.
Simvastatin inhibited proliferation of endometrial cancer cells derived from patients
To expand on our work in established cell lines, we further investigated the effects of
simvastatin on tumor cell growth in primary cultures of endometrial cancer using the MTT
assay. These results demonstrated that the majority of the primary cell cultures responded to
simvastatin, with five of eight achieving an IC50 (range: 8 to 15 uM) after 72 h of treatment
with simvastatin (Figure 6A and D). To further investigate if HMGCR protein expression
was associated with sensitivity to simvastatin, we detected HMGCR protein by Western blot
in all of the primary cultures of endometrial cancer cells (Figure 6B and 6C). We found no
correlation between level of HMGCR protein expression and response to treatment with
simvastatin. For example, primary culture samples 4 and 6 had the least HMGCR
expression, yet sample 6 had a strong response to treatment and sample 4 had a non-
significant response. However, these findings support the possibility that simvastatin
exhibits its anti-proliferative effects through multiple pathways, such as MAPK and AKT/
mTOR pathways, instead of exclusively targeting the mevalonate pathway.
DISCUSSION
The sterols biosynthesis and protein prenylation involved in the mevalonate pathway has
been associated with tumor development and progression. The end products of the
mevalonate pathway are involved in post-translational modifications, which are responsible
for activation of the Ras protein family, regulation of signal transduction and induction of
cell growth and apoptosis. The mevalonate pathway is often overactive in cancer cells and is
thought to be a potential oncogenic pathway (17, 18). In this study, we investigated the anti-
neoplastic activity of simvastatin in endometrial cancer cell lines and primary endometrial
cancer cells. Simvastatin was found to inhibit cellular proliferation, suppress HMGCR
enzymatic activity, cause mitochondrial DNA damage, induce apoptosis and cellular stress,
and block cellular adhesion and invasion. These observations are comparable to recent
studies in breast, liver, melanoma and lung cancer, showing promising anti-tumorigenic
effects of statins on the growth of cancer in vitro and in vivo (19–23). Studies in other cancer
cell types have also shown statins to have anti-metastatic effects such as inhibition of
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adhesion and invasion (24–26). Lastly, statin treatment has also been found to decrease
metastatic burden in cancer mouse models (27, 28).
Simvastatin inhibited the MAPK pathway and exhibited differential effects on the AKT/
mTOR pathways in the ECC-1 and Ishikawa cell lines. Treatment with simvastatin has been
shown to decrease phosphorylation of p42/44 (ERK1/2) and AKT in other cancer cell types
(29, 30). In our study, a minimal change in AKT phosphorylation was seen. Little is known
about the effects of statins on phosphorylated S6 expression in cancer cells. In one study,
treatment with lovastatin in immortalized rat brain neuroblasts resulted in a decrease in
phosphorylation of AKT and its downstream targets including S6 (31). Similar results were
seen in the Ishikawa cell line; however, phosphorylation of S6 was increased in the ECC-1
cell line. The discrepancies between the two cell lines may be due to negative feedback or
alternative signaling pathways taken advantage of by simvastatin to decrease cell
proliferation.
In times of cellular stress, an increase in production of reactive oxygen species (ROS) can
result in DNA damage and subsequently cell death. Studies in cancer cell lines have found
that statin treatment results in the induction of intracellular ROS (8, 32, 33). In addition, our
study demonstrated an associated increase in mitochondrial DNA damage following
treatment with simvastatin. These results indicate that the apoptotic effect induced by
simvastatin is potentially mediated by oxidative stress and consequently mitochondrial DNA
damage.
To date, only one other study has looked at statin’s anti-proliferative effects in endometrial
cancer cells (34). This study analyzed the effects of lipophilic versus hydrophobic statins on
cell proliferation in the Ishikawa endometrial cancer cell line. This same study also used
primary cells from a recurrent endometrial cancer patient, in order to analyze the synergistic
effects of statins and chemotherapy on cell viability. The lipophillic (simvastatin and
lovastatin) but not hydrophilic (pravastatin) statins were found to inhibit proliferation in
endometrial, ovarian and cervical cell lines. Our study demonstrates a more comprehensive
look at the anti-proliferative and anti-metastatic effects of simvastatin in established
endometrial cancer cell lines and further analyzes simvastatin’s anti-proliferative effect
using eight primary culture samples. Our data supports that simvastatin is a potent inhibitor
of cell proliferation in human endometrial cancer cells predominantly through apoptosis and
cell cycle arrest and that using simvastatin to target the mevalonate pathway may be an
effective chemotherapeutic strategy for the treatment of endometrial cancer.
We acknowledge that the IC50 doses of simvastatin used in this in vitro study (14–17 uM
for ECC-1 and Ishikawa, 5–9 uM for primary culture cells) are supra-theraputic compared to
the doses used in hypercholesterolemia patients. However, the range of doses are very
similar to those used in other in vitro studies of simvastatin (1–30 uM) (3–6). The maximum
recommended clinical simvastatin dose is 80 mg/day. The therapeutic dose of simvastatin,
1mg/kg/day, correlates to a serum level of 0.1 uM (35). It is important to consider that cells
in culture are grown in an environment of excess nutrients, which may explain why
concentrations above the therapeutic dose are needed to detect the effects of simvastatin.
Studies using statins (ranging from 0.5–1.5 uM) in mice models have used more
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physiological doses and have shown a decrease in local tumor growth as well as metastasis
(20–22). It is possible that using these supra-therapeutic doses may also cause simvastatin to
have off-target effects which could be reflected in the lack of correlation between HMGCR
expression and response to simvastatin in the primary cultures as well as the variable effects
of simvastatin on downstream signaling pathways in the Ishikawa and ECC-1 cell lines.
Thus, we plan to assess the anti-tumorigenic effects of simvastatin in endometrial cancer
mouse models and correlate these in vivo findings to our work in endometrial cancer cell
lines and primary cultures.
Evidence that simvastatin inhibits HMGCR activity, a critical enzyme in the mevalonate
pathway, makes it a logical option for development of an anti-cancer agent. Currently,
statins are being studied clinically for use in the prevention and treatment of cancer and as
an adjuvant therapy in combination with chemotherapeutic agents. Many epidemiological
studies have shown a correlation between statin use and a relative reduction in the risk of
endometrial, colorectal, gastric, and hepatocellular cancer (9–12, 36, 37). Two colorectal
cancer studies reported a 17–51% reduction in colorectal cancer risk with simvastatin (36,
37). Improved overall survival was seen in patients who used statins one year prior to the
diagnosis of endometrial and ovarian cancers (12). Reduced rates of advanced disease have
been found among prostate cancer patients taking statins at the time of prostatectomy (38).
A clinical trial study comparing advanced liver cancer patients taking pravastatin versus a
placebo showed increased survival amongst those patients who had been given the statin
(39). Breast cancer patients who were given atorvastatin two weeks prior to surgery showed
anti-proliferative effects, with a decrease in Ki-67 staining in those tumors that were
HMGCR positive (40). Although statins used as a single agent have shown some promise,
statins may also be useful in combination with other cytotoxic agents. A phase II study using
simvastatin plus irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) as first-line
chemotherapy in metastatic colorectal cancer showed that time to progression was
prolonged, and no additional adverse effects were seen with the addition of simvastatin (13).
Obese patients often suffer from co-morbidities such as hypercholesterolemia and diabetes
and are at increased risk for the development of endometrial cancer with conceivable worse
outcomes. Thus, it is important to find new strategies to treat these “high risk” patients. With
obesity and endometrial cancer rates on the rise, simvastatin offers a new treatment and
possibly prevention strategy for this disease. Simvastatin is a safe drug that is currently used
by millions worldwide to treat hypercholesterolemia. Simvastatin is effective at inhibiting
cell proliferation through multiple mechanisms in endometrial cancer cell lines and primary
endometrial cancer culture cells, suggesting that using statins to target HMGCR may be
promising for clinical trials in endometrial cancer.
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1. Simvastatin has anti-proliferative and anti-metastatic effects in endometrial
cancer cells, suggesting that statins may have promise for endometrial cancer
treatment.
2. Simvastatin’s anti-tumorigenic effects may be partially mediated through
regulation of the MAPK pathway in endometrial cancer cells.
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Figure 1. Simvastatin inhibits the growth of endometrial cancer cells and HMG-CR activity and
induces cell cycle G0/G1 arrest
ECC-1 and Ishikawa cells were cultured for 24 h and then treated with varying
concentrations of simvastatin in 96 well plates for 72 h. Cell proliferation was assessed by
MTT assay (A). The effect of simvastatin on HMGCR activity levels was determined by
HMG-CoA Reductase Assay. Treatment with simvastatin for 24 h resulted in a dose-
dependent decrease in HMGCR activity in both ECC-1 (B) and Ishikawa (C). Cell cycle
analysis was performed by Cellometer after treatment with the indicated doses of
simvastatin for 24 h. Simvastatin markedly induced cell cycle G0/G1 arrest in ECC-1 (D) in
a dose dependent manner (p<0.05 for doses 10 and 25 μM), while a lesser effect was seen in
Ishikawa (E). * p<0.05
Schointuch et al. Page 15






















Figure 2. Simvastatin induced apoptosis in the ECC-1 (A and C) and Ishikawa (B and D) cell
lines, as evidenced by increased cleaved caspase-3 and decreased BCL-2 expression
ECC-1 and Ishikawa cells were cultured for 24 h and the treated with simvastatin at varying
doses for 24 h. Apoptosis was examined by Annexin V assay via Cellometer. Caspase-3,
BCL-2 and MCL-1 were determined by Western immunoblotting in ECC-1 (E) and
Ishikawa cells (F) after exposure to simvastatin for 16 h. * p<0.05
Schointuch et al. Page 16






















Figure 3. The effect of simvastatin on reactive oxygen species (ROS) generation and
mitochondrial DNA damage in endometrial cancer cell lines
ECC1 and Ishikawa cells were treated with simvastain at different concentrations for 8 h,
and the ROS level was determined using DCFH-DA dye on a plate reader (A and B,
respectively). The ECC-1 and Ishikawa cell lines were treated with the indicated
concentrations of simvastatin for 24 h, and DNA damage was analyzed by qPCR assay (C
and D, respectively). * p<0.05
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Figure 4. The effect of simvastatin on the AKT/mTOR and MAPK pathways in endometrial
cancer cell lines
ECC-1 (A) and Ishikawa (B) cells were treated with simvastatin at different concentrations
as indicated for 18 h. Expression of phosphorylated-AKT, -S6 and -p42/44 was determined
by Western immunoblotting.
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Figure 5. The effect of simvastatin on adhesion and invasion in endometrial cancer cell lines
ECC-1 (A) and Ishikawa (B) cells were cultured for 24 h and then treated with simvastain as
indicated for 2 h in a laminin coated 96 well plate. Adhesion was assessed using a plate
reader. ECC-1 (C) and Ishikawa (D) cells were cultured for 24 h and then treated with
simvastain as indicated for 2 h in a BME coated 96 transwell plate. Invasion was determined
using a plate reader. Treatment with simvastatin resulted in relative inhibition of adhesion
and invasion. * p<0.05
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Figure 6. The effect of simvastatin on eight primary culture endometrial cancer samples
Six out of eight primary cultures endometrial cancer tumors had a decrease in cell
proliferation with an IC50 ranging from 8–15 uM after treatment with indicated doses of
simvastatin for 72 h (A and D). HMGCR expression for each endometrial cancer tumor was
quantified via western blot (B and C). There was no correlation found between HMGCR
expression and response to simvastatin treatment. *NR= no response
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